Chargement en cours...
Intratumoral concentrations of imatinib after oral administration in patients with glioblastoma multiforme
BACKGROUND: Imatinib, an orally administered tyrosine kinase inhibitor of PDGF receptor, c-abl and c-kit, is currently in clinical trials to assess its efficacy in malignant gliomas. Although imatinib does not readily penetrate an intact blood-brain barrier (BBB), the extent to which it distributes...
Enregistré dans:
| Auteurs principaux: | , , , , , , , , |
|---|---|
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
2009
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3927643/ https://ncbi.nlm.nih.gov/pubmed/19768386 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s11060-009-0008-0 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|